Lana

And it might not need to.

See, the firm's betting on distribution instead, choosing to pay Alphabet's Gemini to power parts of its Apple Intelligence features.

And it's leveraging its huge user base to get those tools in front of people stat.

That's it for today.

I'm Lana.

I'll see you tomorrow.

Hey, I'm Lana with your daily brief for Tuesday, March 31st.

Coming up, Eli Lilly's got a sparkling new AI biopharma deal.

And inflation fears are rising, and that could drive up inflation.

We'll also check in with Carl to get his answers to your burning questions.

More on the way, but first...

Eli Lilly just signed a shiny new AI drug development deal with a Hong Kong biotech, hoping the firm's next discoveries will add to its already glittery status.

The U.S.

pharma giant topped the charts with its GLP-1 weight loss and diabetes drugs.

But you're only ever as good as your next hit, so Lilly's trying to make it a big one — and fast.

The firm just agreed to pay $115 million upfront to Insilico Medicine for the rights to an AI-developed GLP-1 diabetes drug.

And if everything goes well — development, approvals, sales — Lilly will fork over as much as $2.75 billion.

But the real prize is bigger, access to Insilico's discovery engine.

The biotech firm has built an end-to-end AI platform that uses generative models to design, develop, and hone potential medicines.

And according to Insilico, it's already produced at least 28 novel drugs, half of which are now in clinical trials.